Hara H, Ohta K, Nishitani H, Takegami T, Okamoto S, Hayashi K, Ohta M
Clinical Research Center, Utano National Hospital, Kyoto, Japan.
Clin Chem. 1990 Nov;36(11):1967-9.
We developed a highly sensitive enzyme immunoassay (EIA) for measuring IgG and IgM antibodies against human skeletal muscle (SM) component and tested sera from 100 patients with myasthenia gravis (MG), 59 with thymoma and 41 without thymoma. We found that the frequency of anti-SM IgG antibodies was significantly higher in MG patients with (81%) than without (37%) thymoma. The titers of the anti-SM IgG antibodies measured by EIA correlated well with those measured by RIA (r = 0.81, P less than 0.01). We also found that 12% of the myasthenic patients with thymoma and 15% without it had anti-SM IgM antibodies. There was no correlation between the titers of the IgG and IgM antibodies. Our EIA provides a measure of anti-SM antibodies that is of comparable sensitivity to that of RIA.
我们开发了一种用于检测抗人骨骼肌(SM)成分IgG和IgM抗体的高灵敏度酶免疫测定法(EIA),并检测了100例重症肌无力(MG)患者、59例胸腺瘤患者和41例无胸腺瘤患者的血清。我们发现,有胸腺瘤的MG患者中抗SM IgG抗体的频率(81%)显著高于无胸腺瘤的患者(37%)。通过EIA检测的抗SM IgG抗体滴度与通过放射免疫分析(RIA)检测的滴度相关性良好(r = 0.81,P<0.01)。我们还发现,有胸腺瘤的肌无力患者中有12%以及无胸腺瘤的患者中有15%存在抗SM IgM抗体。IgG和IgM抗体滴度之间无相关性。我们的EIA提供了一种抗SM抗体的检测方法,其灵敏度与RIA相当。